James Freston
Gastroenterology · Farmington, CTNPI 1184629875
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $769,787 of the $772,114 with a category attached, or 99.7%. 21 manufacturers reported payments, led by Viiv Healthcare Company at 37.5% of the total. Reporting peaked in 2019 at $192,199 and has fallen 52.2% since, to $91,823 in 2025. Among gastroenterology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $2913.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$289K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$88K
- GSK$81K
- Intercept Pharmaceuticals, Inc.$81K
- Actelion Pharmaceuticals, Ltd$64K
- Pfizer$28K
- plus $139K from 15 others
Across 44 payments — averaging $2797.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$99K
- AbbVie$12K
- Ionis Pharmaceuticals, Inc.$5K
- Boehringer Ingelheim International GmbH$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Eli Lilly$1K
- plus $750 from 1 others
What the payments were for
- Consulting fees$769,787100%
- Speaking & faculty fees$1,3000%
- Travel & lodging$6680%
- Food & beverage$3590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 49 | $289,163 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 57 | $88,400 |
| GSK | 21 | $81,225 |
| Intercept Pharmaceuticals, Inc. | 12 | $81,000 |
| Actelion Pharmaceuticals, Ltd | 18 | $64,449 |
| Pfizer | 19 | $28,485 |
| Boehringer Ingelheim International GmbH | 36 | $22,625 |
| Biogen | 5 | $21,060 |
| AbbVie | 3 | $19,600 |
| UCB SA | 1 | $12,450 |
| Janssen Research & Development, LLC | 3 | $12,245 |
| AstraZeneca | 18 | $12,188 |
| Daiichi Sankyo Inc. | 2 | $10,300 |
| Bristol Myers Squibb | 3 | $10,214 |
| Seagen Inc. | 2 | $6,550 |
| Madrigal Pharmaceuticals | 8 | $4,125 |
| Ionis Pharmaceuticals, Inc. | 2 | $2,925 |
| Shionogi Inc | 1 | $2,633 |
| Astellas Pharma Global Development | 1 | $1,300 |
| Astrazeneca UK Limited | 1 | $1,060 |
| Strongbridge US Inc. | 3 | $119 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$772,114 in reported general payments places this provider in the 95th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Farmington
- Houman RezaizadehFarmington$93K
- Neil ParikhFarmington$68K
- Paul FeuerstadtHamden$1M
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
- Michael EinsteinHartford$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.